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This cross-sectional study based on self-administrated questionnaire was conducted to investigate knowledge, related factors,
and sources of information regarding islet transplantation in patients with type 1 diabetes in Japan. Among 137 patients who
provided valid responses, 67 (48.9%) knew about islet transplantation. Their main source of information was newspapers or
magazines (56.7%) and television or radio (46.3%). However, 85.8% of patients preferred the attending physician as their source
of information. Although more than half of the patients were correctly aware of issues related to islet transplantation, the
following speciﬁc issues for islet transplantation were not understood or considered, and there was little knowledge of them:
need for immunosuppressants, lifestyle and dietary adaptations, fewer bodily burdens, and complications. The experience of
hypoglycaemia, a high level of academic background, frequent self-monitoring of blood glucose, and the use of continuous
subcutaneous insulin infusion were related to higher knowledge about islet transplantation.
1.Introduction
As an alternative to intensive insulin injection therapy, pan-
creatic transplantation and islet transplantation are being
established hoping for a radical cure for patients who
are at serious risk of poor glycemic control. Although
pancreatic transplantation could cure type 1 diabetes, its
outcomes are not necessarily favorable than conventional
therapy, due to invasive surgical procedure and/or toxicity of
immunosuppression procedure [1, 2]. Islet transplantation
once dramatically progressed by the establishment of the
Edmonton protocol [3]. Initially, short-term eﬀects by islet
transplantation had demonstrated that it achieved a highly
improved rate of temporal insulin independency [3]. But
original Edmonton protocol with nondepleting anti-T-cell
antibody did not achieve longitudinal insulin indepen-
dency [4]. So the current islet transplantation protocol
needs an active immunosuppression procedure, though it
is still a less “surgically” invasive procedure than pancreatic
transplantation [5–7]. In spite of these limited eﬀects and
physical burden, patients with islet transplantation report
less concern about hypoglycaemia [8, 9], which is one of
the most signiﬁcant factors associated with quality of life
in patients with type 1 diabetes. This study suggests that
islet transplantation should improve quality of life of type
1 diabetic patients, though its actual improvement remains
unclear because of small sample size [10].
Islet transplantation in Japan is conducted from
nonheart-beatingdonorsbecausetherearefewheart-beating
brain-dead donors in Japan per year and their pancreata are
used for pancreas transplantation. The donation procedure
from a nonheart-beating donor is more complicated than
t h a tf r o mab r a i nd e a dd o n o r[ 11]. Pancreatic islet trans-
p l a n t a t i o nh a sb e e nc o n d u c t e d3 4t i m e si n1 8p a t i e n t si n2 Journal of Transplantation
Japan [12] while 649 times in 325 patients between 1999 to
2007inwesterncountriesaccordingtotheCollaborativeIslet
Transplant Registry [13].
Although the donor shortage and technical issues limit
the application of islet transplant at present, the dramatic
progress of procedures may solve the limitations: improve-
ment in methods for the isolation and preservation of
islet cells [14, 15], xenotransplantation or reproduction islet
transplantation [16, 17], and no requirement for multiple
donors [18]. Moreover, a recent immunosuppressive proce-
dure that is now undergoing a phase III trial [19] and the
use of glucagon-like peptide-1 receptor agonist after islet
transplantation [20, 21]s h o wi m p r o v e db e t a - c e l lf u n c t i o n
and prolonged insulin independence. These progressive
ﬁndings may encourage patients and medical professionals
who consider application of islet transplantation, and then
islet transplantation may be generally available for the
medical treatment of type 1 diabetes in Japan in the near
future. Taking this into account, it is necessary to prepare a
system for responding to forthcoming patient needs about
islet transplantation.
Previous research shows that posttransplantation pa-
tients often ﬁnd it diﬃcult to bear the need for stricter
restriction of their dietary habits and physical activity than
during the pretransplantation period in order to maintain
control of their blood glucose level [22]. In addition,
posttransplantation patients need to ensure adequate dietary
behavior in order to avoid overloading of the grafted islets,
which is unnecessary in pancreas transplantation [23]. This
sense of bearing a burden may be caused by the gap between
reality and the patient’s pre-transplant idea of daily life after
transplantation; patients might think thatthey will no longer
be restricted in their lifestyle habits by diet therapy, exercise
therapy, and insulin injections. In order to resolve the
problem presented by this gap, it is necessary to understand
the patient’s knowledge and perceptions related to treatment
and supply accurate information when medical professionals
discuss options for medical treatment with patients [24].
It is also important to supply information that the patient
requires and supply it from suitable sources in order to
improve its acceptability to patients.
In the present study, a self-administered questionnaire
survey was provided to type 1 diabetes patients to clarify (1)
their knowledge of islet transplantation and (2) actual and
desired information sources about islet transplantation.
2. Methods
2.1. Setting and Participants. This cross-sectional observa-
tional study based on a self-administered questionnaire was
conducted at the diabetes clinic of four general hospital
in 2008 July to November type 1 diabetes patients who
were being treated at the diabetes clinic were enrolled. The
inclusion criteria were as follows: (1) age between 20 and
75 years and (2) at least 6 months since diagnosis with type
1 diabetes. Patients not ﬂuent in Japanese or with cognitive
impairment were excluded.
When patients visited the clinic, a clinician assessed
whether they met the inclusion criteria. The nature of
the study was explained to eligible patients by one of the
investigators. For ethical reasons, it is unavoidable to make
referenceaboutislettransplantationwhenresearchassociates
explain this study to patients and obtain consent. So a simple
outline of islet transplantation was therefore given to all
participants. After providing written informed consent to
participate in the study, each patient was asked to complete a
questionnaire. The questionnaire was collected immediately
after the patient completed it.
2.2. Questionnaire. The content validity and face validity of
the questionnaire were conﬁrmed by a panel of experts in
each specialist area: islet transplantation, treatment, nursing,
and research using questionnaires. The following question-
naire items were derived from existing guidelines about islet
transplantation or generated from existing literature by the
authors. Face validity and content validity were conﬁrmed
by pretest in 6 patients with type 1 diabetes.
Patients were asked whether they were aware of the term
“islettransplantation”beforetheirparticipationinthisstudy.
Patients who answered that they did know the term were
then asked about their detailed perceptions by asking them
whether they agreed or disagreed with the 10 statements
about islet transplantation (Table 3). Some of the statements
were not necessarily correct. The patients were asked to
answer the items on a four-point Likert scale (“agree,”
“moderately agree,” “moderately disagree,” “disagree”), or to
respond “Do not know.”
Patients who answered that they knew about islet
transplantation were asked where they obtained informa-
tion about it. All patients were then asked whether they
wanted information about islet transplantation. Those who
replied that they wanted information were then asked which
kind of information source they preferred. The questions
about information source were both in multiple-choice
form: attending physician, other physicians, other medical
professionals, family, patients with type 1 diabetes or patient
society, newspaper/magazine, TV/radio, and the Internet.
The following variables were investigated as subjects’
clinical characteristics: body mass index (BMI, kg/m2), du-
ration of diabetes (years), current treatment (insulin self-
injection (yes/no), continuous subcutaneous insulin infu-
sion (CSII) (yes/no)), frequency of insulin injection, and
self-monitoring of blood glucose (SMBG). The following
symptom-related characteristics were investigated: whether
the patient had complications related to diabetes (retinopa-
thy, nephropathy, neuropathy (yes/no)); frequency and
details of hypoglycaemia in the last 4 weeks. Other back-
ground characteristics investigated were as follows: gender,
age, educational status, living status, marital status, occupa-
tional status, and social support.
2.3. Statistical Analysis. First, descriptive statistics for each
variable were tabulated. Next, univariate logistic regression
analysis was performed to assess which factors aﬀected the
knowledge of islet transplantation (“know” was scored 1;
“do not know” was scored 0). Subject characteristics were
treated as independent variables. SAS version 9.13 softwareJournal of Transplantation 3
Table 1: Subject characteristics (N = 137).
Number (%), mean ±SD
Gender (male) 76 (55.5)
Age (years) 52.0 ±12.7
BMI (kg/m2)(1) 21.9 ±11.4
Educational status
Junior high school 9 (6.6)
High school 60 (43.8)
Junior college 24 (17.5)
University 43 (31.4)
Occupation status
Full time 70 (51.1)
Part time 19 (13.9)
None 42 (30.7)
Others 5 ( 3.6)
Living with others 111 (81.0)
Married 100 (73.0)
Onset of diabetes (age) 38.2 ±14.8
Duration of diabetes (years) 13.7 ±10.8
Diabetic complication
Neuropathy 36 (26.3)
Retinopathy 37 (27.0)
Nephropathy 17 (12.4)
Current treatment
Insulin injections 124 (90.5)
CSII(2) 13 ( 9.5)
HbA1C (NGSP, %) 7.9 ±1.2
SMBG (times) 3.0 ±1.8
Hypoglycemic episode (yes) 109 (79.6)
Hypoglycemic episode (times) 5.2 ±4.5
Continuation values are means ± SD.
(1)Body mass index.
(2)Continuous subcutaneous insulin infusion.
(SAS Institute, Cary, NC, USA) was used for statistical anal-
ysis, and the level of signiﬁcance was set at P<0.05.
2.4. Results. Of the 143 eligible patients who visited the
clinic during the study period, 137 (95.8%) completed
the questionnaire. Table 1 shows the characteristics of the
subjects.
Sixty-seven (48.9%) patients answered that they knew
the term “islet transplantation.” Table 2 shows the actual
and desired sources of information. Of the 137 subjects,
120 (87.6%) patients answered that they wanted infor-
mation about islet transplantation. Patients used newspa-
pers/magazines (56.7%) and TV/radio (46.2%) as infor-
mation sources most frequently. On the other hand, the
“attending physician” was the most desired information
source (85.8%).
Table 3 shows knowledge and detailed perceptions of
islet transplantation. Among the correct statements, more
than half of the patients answered “agree”/“moderately
agree” to the following items: “islet transplantation stabilizes
blood sugar level”; “islet transplantation is expensive”;
Table 2: Actual/desired information sources islet transplantation.
Actual(1) n = 67 Desired(2) n = 120
n (%) n (%)
Attending physician 9 (13.4) 103 (85.8)
Other physician 5 (7.5) 35 (29.4)
Other medical
professionals 2 (3.0) 32 (26.7)
Family 2 (3.0) 2 (1.7)
Other T1DM patients or
patient society 6 (9.0) 22 (18.3)
Newspaper/magazine 38 (56.7) 43 (35.8)
TV/radio 31 (46.2) 31 (25.8)
Internet 17 (25.4) 36 (30.0)
(1)Only the subjects who answered that they knew islet transplantation.
(2)Onlythesubjectswhoansweredthattheyrequiredinformationaboutislet
transplantation.
“there are few donors in Japan.” For the items “islet
transplantation causes fewer physical burdens” and “islet
transplantation is conducted mainly in a person having dif-
ﬁculty achieving glycemic control” the answer tended to be
“disagree”/“moderately disagree” (38.8% and 47.7%, resp.).
About half of the patients answered “do not know” to the
items “complication of islet transplantation is severe,” “islet
transplantation makes immunosuppressant indispensable”
(53.7% and 44.8%, resp.).
Table 4 shows the relationship between the knowledge of
islet transplantation and patients’ characteristics. Variables
that showed signiﬁcant association with a good level of
knowledge were high educational status (odds ratio (OR) =
2.45 (95% CI 1.23–4.88)), frequent SMBG (OR = 1.26 (1.04–
1.52)), and experience of hypoglycemic events within the last
4w e e k s( O R= 4.66 (1.75–12.4)).
3. Discussion
The HbA1C level, BMI, and other demographic character-
istics in the subjects of this study were similar to those
in a previous nationwide survey [25]. So results in this
study can be regarded as reﬂecting the common sense of
Japanese patients with type 1 diabetes. Almost half of the
subjects in this study knew about islet transplantation. The
sources of information of the patients who knew about
pancreatic islet transplantation were mainly the mass media,
but they regarded their attending physician as the most
acceptable information source. Little information about islet
transplantationisoﬀeredbymedicalprofessionalsatpresent.
Even if patients are interested in islet transplantation, it
is not easy for them to obtain valid information from
medical professionals. It is to be expected that physicians
have diﬃculty in supplying information because islet trans-
plantation is still a special treatment, and even attending
physicians do not have suﬃcient information. Since the mass
media disseminate population-based information, it is not
necessarily appropriate for individual patients. It is often
hard for patients to know what is appropriate information4 Journal of Transplantation
Table 3: Detailed perception of islet transplantation (N = 67).
Agree Moderately
agree
Moderately
disagree Disagree Do not know
n (%) n (%) n (%) n (%) n (%)
Stabilization of blood sugar level 29 (43.3) 29 (43.3) 2 (3.0) 1 (1.5) 6 (9.0) A(1)
Its expensive 39 (58.2) 9 (13.4) 1 (1.5) 0 (0.0) 18 (26.9) A
There are few donors 33 (49.3) 10 (14.9) 2 (3.0) 1 (1.5) 21 (31.3) A
Fewer physical burdens 7 (10.4) 11 (16.4) 7 (10.4) 19 (28.4) 23 (34.3) A
Indispensable
Immunosuppressant 25 (37.3) 8 (11.9) 2 (3.0) 1 (1.5) 30 (44.8) A
Performed positively abroad 18 (26.9) 16 (23.9) 6 (9.0) 5 (7.5) 22 (32.8) A
Only for poor control patients 18 (26.9) 11 (16.4) 7 (10.4) 25 (37.3) 6 (9.0) A
Complication is severe 11 (16.4) 7 (10.4) 10 (14.9) 3 (4.5) 36 (53.7) B
Possible at any large hospital 0 ( 0.0) 6 (9.0) 7 (10.4) 39 (58.2) 14 (20.9) B
Become insulin-free 26 (38.8) 22 (32.8) 9 (13.4) 3 (4.5) 7 (10.4) C
Item description was abbreviated.
(1)A: correct, B: wrong, C: not always correct.
Table 4: Factors related to knowledge about pancreatic islet trans-
plantation (N = 137; logistic simple linear regression analysis).
Variable
Knew islet transplantation
OR [95% CI]
Gender (female versus
male) 1.15 [0.59–2.25]
Age 0.99 [0.96–1.01]
Education (≥12 years
versus <12 years) 2.45 [1.23–4.88] ∗
Body mass index 0.92 [0.82–1.03]
Onset of diabetes (age) 0.99 [0.99–1.04]
Duration of diabetes
(years) 1.00 [0.97–1.04]
Diabetic complication
Neuropathy 1.24 [0.58–2.64]
Retinopathy 0.73 [0.34–1.56]
Nephropathy 0.53 [0.18–1.52]
HbA1c 0.87 [0.66–1.16]
SMBG 1.26 [1.04–1.52] ∗
Hypoglycemic episode (yes
versus none) 4.66 [1.75–12.4] ∗∗
Hypoglycemic episode
(times) 0.78 [0.60–1.01]
Current treatment (CSII
versus injection) 15.1 [1.90–119] ∗
OR: odds ratio, CI: conﬁdence interval ∗P<0.05 ∗∗P<0.01 when OR is
more than 1, it is assumed that patients knew about islet transplantation.
and sometimes they might choose to accept inappropriate
information [26]. There is thus an unmet need that should
be resolved in order to prevent inappropriate understanding
of islet transplantation.
In spite of this information shortage, patients have ap-
propriate perceptions of the expense of islet transplantation
and the shortage of donors. However, these are common
problems not only in islet transplantation but also in the
transplantation of organs generally, and this is probably
widely understood. On the other hand, the perception
of items speciﬁc to islet transplantation was diﬀerent.
Prognosis-related items related to glycemic stability and
insulin-free status [27] were well understood whereas the
treatment advantage of fewer physical burdens was less well
understood [3]. Furthermore, disadvantages and complica-
tions of islet transplantation tend to be unrecognized. This
shows that patients who had partial knowledge about islet
transplantation were biased toward the idea of a favorable
treatment outcome. It is necessary to provide patients with
moreinformationabouttheadvantagesanddisadvantagesof
the islet transplantation procedure to enable them to arrive
at a valid, informed choice. Especially, medical professionals
must explain carefully that islet transplantation is a develop-
ing procedure, with insuﬃcient information about clinical
outcome [28].
Experience of hypoglycaemia and frequent SMBG were
related to good knowledge of islet transplantation. Hypo-
glycemic events lead to discouragement in the daily life of
patients [29]. Frequent SMBG is also a burden for patients.
I np a r t i c u l a r ,t h eb u r d e no fS M B Gw o u l db em o r es e v e r ei n
patients with poor glycemic control because the frequency
of SMBG increases as glycemic control worsens [30]. Thus,
patients would desire radical treatment because their quality
of life is threatened by hypoglycaemia or frequent SMBG
due to poor glycemic control. The relationship between
educationalstatus,CSIIusage,andknowledgemightindicate
that health literacy and the decision to seek new treatment
would also motivate patients to seek information about islet
transplantation.
Some of the limitations of this study will now be dis-
cussed. First, whether these ﬁndings are speciﬁc to Japanese
type 1 diabetic patients remains unclear, because this study
did not contain a control group of nondiabetic adults.
Second,asmentionedinSection 2,wegavebriefinformation
about islet transplantation to the patients when we obtainedJournal of Transplantation 5
their informed consent. Although the information given
to them consisted only of a simple outline of the islet
transplantation procedure, there might have been some
eﬀects on the patients’ responses, especially to the question
about their detailed perceptions. Additionally, since the
information was brief, subjects should answer the question
with ambiguous knowledge about islet transplantation. For
example, if the information about requirement for multiple
donors was given to the subjects, they could have negative
impression towards islet transplantation.
Despite these weaknesses, this is the ﬁrst study that
clariﬁed knowledge, detailed perceptions, and information
sources regarding islet transplantation in type 1 diabetes
patientsinJapan.Theseresultsmayprovideavaluablesource
of reference for medical professionals oﬀering patients islet
transplantation as a treatment option.
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